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Glaucoma Among IndividualsWith African Ancestry
The Genetics of Glaucoma in People of African Descent (GGLAD) Consortium
IMPORTANCE Primary open-angle glaucoma presents with increased prevalence and a higher
degree of clinical severity in populations of African ancestry compared with European or
Asian ancestry. Despite this, individuals of African ancestry remain understudied in genomic
research for blinding disorders.
OBJECTIVES To perform a genome-wide association study (GWAS) of African ancestry
populations and evaluate potential mechanisms of pathogenesis for loci associated with
primary open-angle glaucoma.
DESIGN, SETTINGS, AND PARTICIPANTS A 2-stage GWASwith a discovery data set of 2320
individuals with primary open-angle glaucoma and 2121 control individuals without primary
open-angle glaucoma. The validation stage included an additional 6937 affected individuals
and 14 917 unaffected individuals using multicenter clinic- and population-based participant
recruitment approaches. Study participants were recruited from Ghana, Nigeria, South Africa,
the United States, Tanzania, Britain, Cameroon, Saudi Arabia, Brazil, the Democratic Republic
of the Congo, Morocco, Peru, andMali from 2003 to 2018. Individuals with primary
open-angle glaucoma had open iridocorneal angles and displayed glaucomatous optic
neuropathy with visual field defects. Elevated intraocular pressure was not included
in the case definition. Control individuals had no elevated intraocular pressure and no signs of
glaucoma.
EXPOSURES Genetic variants associated with primary open-angle glaucoma.
MAIN OUTCOMES ANDMEASURES Presence of primary open-angle glaucoma. Genome-wide
significance was defined as P < 5 × 10−8 in the discovery stage and in themeta-analysis of
combined discovery and validation data.
RESULTS A total of 2320 individuals with primary open-angle glaucoma (mean [interquartile
range] age, 64.6 [56-74] years; 1055 [45.5%] women) and 2121 individuals without primary
open-angle glaucoma (mean [interquartile range] age, 63.4 [55-71] years; 1025 [48.3%]
women) were included in the discovery GWAS. The GWAS discovery meta-analysis
demonstrated association of variants at amyloid-β A4 precursor protein-binding family B
member 2 (APBB2; chromosome 4, rs59892895T>C) with primary open-angle glaucoma
(odds ratio [OR], 1.32 [95% CI, 1.20-1.46]; P = 2 × 10−8). The association was validated in an
analysis of an additional 6937 affected individuals and 14 917 unaffected individuals (OR, 1.15
[95% CI, 1.09-1.21]; P < .001). Each copy of the rs59892895*C risk allele was associated with
increased risk of primary open-angle glaucomawhen all data were included in a meta-analysis
(OR, 1.19 [95% CI, 1.14-1.25]; P = 4 × 10−13). The rs59892895*C risk allele was present at
appreciable frequency only in African ancestry populations. In contrast, the rs59892895*C
risk allele had a frequency of less than 0.1% in individuals of European or Asian ancestry.
CONCLUSIONS AND RELEVANCE In this genome-wide association study, variants at the APBB2
locus demonstrated differential association with primary open-angle glaucoma by ancestry. If
validated in additional populations this findingmay have implications for risk assessment and
therapeutic strategies.
JAMA. 2019;322(17):1682-1691. doi:10.1001/jama.2019.16161
Related article page 1705
Supplemental content
Author/Group Information: The
Genetics of Glaucoma in People of
African Descent (GGLAD) Consortium
members appear at the end of the
article.
Corresponding Author:Michael A.
Hauser, PhD, Duke University, 300 N
Duke St, Room 50-101, Durham, NC
29901 (mike.hauser@duke.edu).
Research
JAMA | Original Investigation
1682 (Reprinted) jama.com
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Duke Medical Center Library User  on 11/05/2019
P rimary open-angle glaucomaaffectsmillions of peopleworldwide and is a leading cause of irreversibleblindness.1,2 Genome-wide association studies
(GWASs) have identified more than 15 genetic loci associated
with increased risk of primary open-angle glaucoma in popu-
lations with European or Asian ancestry,3,4 and these results
have been supported by analyses of glaucoma-associated
quantitative traits, such as intraocular pressure (IOP) and ver-
tical cup-to-disc ratio.5 In contrast, although GWASs of indi-
viduals of African ancestry have been performed,6,7 no
genome-wide significant loci have been identified to date in
this disproportionately affected population. Studies have
shown that while individuals of European ancestry older
than 40 years exhibit a disease prevalence of 1%, the preva-
lence is markedly higher in individuals with African ancestry
older than 40 years (up to 6.8%).2,8,9 Primary open-angle
glaucoma also has earlier onset and is more severe in indi-
viduals of African ancestry.10-12 A 2018 GWAS examining pri-
mary open-angle glaucoma in a multiethnic sample, the
Genetic Epidemiology Research on Adult Health and Aging
cohort, confirmed that there is a higher prevalence of pri-
mary open-angle glaucoma in individuals of African ancestry
(16.1%) compared with individuals of East Asian (9.9%) and
European (7.4%) ancestry.13
The objective of this study was to address this disparity
in genomic science research by performing a GWAS of pri-
mary open-angle glaucoma via a multicenter research part-
nership to obtain biological insights into disease pathogen-
esis in individuals with African ancestry.
Methods
Study Populations
The study populations comprised 2 groups: the GWAS
discovery stage followed by a validation stage. The valida-
tion stage included 2 separate meta-analyses. All partici-
pants were recruited using the same criteria in both stages.
Individuals with primary open-angle glaucoma, control
individuals without primary open-angle glaucoma, and eye
and brain tissue donors (or family members of deceased
donors) were enrolled after written informed consent was
obtained from each participant, in full adherence to the
Declaration of Helsinki. All relevant local and hospital insti-
tutional review boards approved the study. Participant
ancestry was self-reported.
For the GWAS discovery stage, study participants of
African ancestry were recruited from Ghana, Nigeria, South
Africa, and Duke University (Durham, NC), where the same
phenotype definition was applied to diagnose primary
open-angle glaucoma.3,14,15 Individuals with primary open-
angle glaucoma were defined by the presence of glaucoma-
tous optic neuropathy (defined as loss of neuroretinal rim
with a vertical cup-to-disc ratio of >0.7 or an intereye asym-
metry >0.2 and/or notching attributable to glaucoma) with
compatible visual field loss, open angles on gonioscopy, and
absence of secondary causes of glaucomatous optic neu-
ropathy. Elevation of IOP was not a criterion in inclusion or
exclusion of patients. Patients who were unable to give
informed consent or those with secondary glaucoma due to
trauma, uveitis, neovascularization, exfoliation syndrome,
or pigment dispersion were excluded. Control individuals
were recruited in a hospital-based or population-based
manner. Hospital-based control individuals were older than
40 years and were confirmed to have no sign of glaucoma or
other major eye diseases. These participants had an IOP of
less than 21 mm Hg with open angles at the time of recruit-
ment, healthy optic nerves, normal visual fields, and no
family history of glaucoma. Population-based control indi-
viduals were matched by hospital and ancestry and were
healthy individuals older than 40 years. The participating
institutions are listed in the eAppendix in the Supplement.
The sample collections from the discovery GWAS analysis
were ascertained or reexamined between January 1, 2012,
and December 31, 2017.
The studydesignandgenotypingmethod for the 7 sample
collections analyzed in the first validationmeta-analysis have
beenpreviously described.6,7,13,16-18 The studynamesof these
collections are listed in theeAppendix in theSupplement. The
sample collections were ascertained or reexamined between
January 1, 2003, and December 31, 2018.
The second validation meta-analysis included individu-
als with primary open-angle glaucoma and matched control
individuals fromMali, Cameroon,Nigeria (Lagos,Kaduna, and
Enugu), Brazil, Saudi Arabia, the Democratic Republic of the
Congo,Morocco, and Peru. The participating hospital institu-
tions are listed in the eAppendix in the Supplement. These
sample collections were ascertained or reexamined between
January 1, 2015, and December 31, 2018.
Genotyping andQuality Control Procedures
For the GWAS discovery stage, genome-wide genotypingwas
performed using the Illumina OmniExpress beadchip, which
directly assessedmore than 700000 single-nucleotide poly-
morphism(SNP)markersacross thehumangenome.Thisgeno-
typing array has been successfully used in multiple genome-
wide scans,19,20 including scans for primary open-angle
glaucomaandother formsof glaucoma.14,21 Further details on
GWAS genotyping and quality control procedures are in-
cluded in the eAppendix in the Supplement.
Key Points
Question Are there differences in genetic risk factors for primary
open-angle glaucoma based on ancestry?
Findings In this multistage, case-control, genome-wide
association study that included 26 295 participants, the amyloid-β
A4 precursor protein-binding family Bmember 2 (APBB2) locus
was significantly associated with primary open-angle glaucoma
among individuals of African ancestry (odds ratio, 1.19 per copy of
the risk allele for single-nucleotide polymorphism
rs59892895T>C), but not of European or Asian ancestry.
Meaning This study identified a single-nucleotide polymorphism
that demonstrated differential association with primary
open-angle glaucoma by ancestry.
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The first validation meta-analysis for amyloid-β A4 pre-
cursor protein-binding family B member 2 (APBB2; Refseq
NM_004307) rs59892895 was performed with genome-wide
genotyping data from previously described matched pri-
mary open-angle glaucoma case-control data sets. The sec-
ond validation meta-analysis for APBB2 rs59892895 was
performed with the Sequenom MassArray primer extension
system, with the genotypes further verified with Applied
Biosystems Taqman assays.
Fine-scale imputation analysis using the 1000 Genomes
Project cosmopolitan reference panel was performed to
increase the density of the discovery GWAS. The IMPUTE
version 2 software package was used to perform the
imputation.22 Stringent quality control was applied on
the imputed data by only including imputed genotypes
with an information score of at least 0.95 and by only
including SNPs with minor allele frequency of at least 1%.
The imputation accuracy of APBB2 rs59892895T>C
was validated with direct genotyping using the MassArray
(Sequenom) and Taqman (Applied Biosystems) systems
(with >99% concordance).
Immunohistochemistry and Image Analysis ofAPBB2
and β-Amyloid in Donor Retina Tissues
APBB2wasshownto increaseβ-amyloid flux throughboth the
amyloidogenic and nonamyloidogenic pathways of amyloid
precursor protein (APP) processing.23 Donor eyes were se-
lected from a tissue collection obtained from the Iowa Lions
Eye Bank within 8 hours after death (eTable 1 in the Supple-
ment). Retinal tissue sections from the donor eyes were as-
sessed for APBB2 and β-amyloid expression using immuno-
histochemistry and image analysis. Further details on the
experimental methods are included in the eAppendix in the
Supplement.
Immunohistochemistry and Image Analysis ofAPBB2
and β-Amyloid in Primary Visual Cortex Tissues
All donor samples (eTable 2 in the Supplement) were
obtained from the Duke Kathleen Price Bryan Brain Bank
and Biorepository and were matched for age and Alzheimer
disease severity stage using the Braak classification.24,25
Sections from the primary visual cortex of the donor
samples were assessed for APBB2 and β-amyloid expression
using immunohistochemistry and image analysis. Further
details on the experimental methods are included in the
eAppendix in the Supplement.
Statistical Analysis
An analysis of the discovery GWAS and follow-up validation
stages were prespecified. The evaluation of previously
described loci and their consequences on primary open-
angle glaucoma risk in the cohort of participants with Afri-
can ancestry as well as studies exploring potential patho-
genic mechanisms related to APBB2 were undertaken in an
exploratory, post hoc manner.
For the discovery GWAS analysis, the association
between individual SNP genotypes and primary open-angle
glaucoma risk was modeled additively for each copy of the
minor allele using logistic regression adjusted for the top 3
principal components of population stratification using
PLINK, version 1.9 (details on principal component analysis
are included in the eAppendix in the Supplement).26 For
imputed genotypes, the information content for allele dos-
age (range, 0-1; 1 indicates perfect information) were
included into the association test model to account for and
average across imputation uncertainty. The assumptions of
this logistic regression model were that the effective sample
size was sufficiently large to allow for χ2-distributed test
statistics (eg, the Wald statistic for logistic regression) to be
valid, for the observations to be independent of one
another, and for only a low degree of collinearity to exist
between the independent variables. The model assump-
tions were all met.
Genomic inflation (λgc) in the GWAS discovery stage was
estimated using the median regression test statistic. The ge-
nomic inflation factor is presented for eachof the4GWASdis-
covery sites as well as for the GWAS discovery meta-analysis
in eFigure 1 in theSupplement. For theGWASdiscovery analy-
sis,P < 5 × 10−8 (2-sided test)was considered statistically sig-
nificant. In the validation stages, the association between
APBB2 rs59892895andprimaryopen-angleglaucomariskwas
measured using logistic regression for an additivemodel. Be-
cause only 1 SNP (APBB2 rs59892895) was tested in the first
and second validation stages, P < .05 (2-sided test) was con-
sidered statistically significant for eachvalidation stage.Meta-
analyses were conducted using the inverse-variance fixed-
effectsmethod (eAppendix in the Supplement).27 Intercohort
heterogeneity was assessed for the GWAS discovery and vali-
dation stages.
Previous case-control studies of primary open-angle
glaucoma in individuals with European and Asian ancestry
have robustly implicated at least 26 SNPs mapping to 15 dis-
tinct gene loci (TMCO1, FMNL2, CADM2, AFAP1, THSD7A,
CAV1-CAV2, ANGPT1, CDKN2B-AS, ABCA1, LMX1B, PLCE1,
TMTC2, SIX6, TCF12, and GAS7), accompanied by validation
in at least 2 independent studies.3,13,14,28-31 The association
between these 26 SNPs and primary open-angle glaucoma
risk were tested using logistic regression in the collections
from individuals with African ancestry, which included 5153
affected individuals and 10014 unaffected individuals with
available genotyping data. An inverse-variance, fixed-effects
meta-analysis was conducted to summarize the estimates.
A case-only quantitative trait locus analysis was per-
formed between APBB2 rs59892895T>C and 2 clinical para-
meters: maximum IOP and vertical cup-to-disc ratio at the
time of examination (using the mean ratio if available for
both eyes). The association between APBB2 rs59892895T>C
and the clinical parameters was assessed using linear
regression with sex and age as covariates. The fluorescence
intensity data from the immunohistochemical analysis
(eAppendix in the Supplement) of retina and primary visual
cortex tissues were analyzed with regards to APBB2
rs59892895T>C carrier status using a linear mixed model
incorporating additional random effect terms for individual
(for both retina and visual cortex data) and Braak stage (for
visual cortex data only).
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Results
A total of 26295 individuals were included in the study. The
number of individuals with primary open-angle glaucoma
and control individuals analyzed in the GWAS and valida-
tion stages are presented in the Table (quality control results
and handling of population stratification can be found in
the eAppendix and eFigures 1, 2, and 3 in the Supplement).
The discovery meta-analysis identified a genome-wide sig-
nificant association at 1 locus on chromosome 4, character-
ized by multiple SNPmarkers showing high pairwise linkage
disequilibrium (Figure 1; summary statistics for the GWASs
are publicly available per the data sharing statement). The
association mapped to the APBB2 rs59892895T>C locus
(Figure 2), whereby the minor C allele was observed to be
associated with increased risk of primary open-angle glau-
coma (per-allele odds ratio [OR], 1.32 [95% CI, 1.20-1.46];
P = 2 × 10−8).
The APBB2 rs59892895 association was tested in the
first validation meta-analysis comprising 7 independently
ascertained sample collections from participants with
African ancestry (Table). This first validation data set
with prior genome-wide genotyping data available for 5401
individuals with primary open-angle glaucoma and 13 015
individuals without primary open-angle glaucoma had
greater than 90% statistical power to validate an SNP with a
minor allele frequency as low as 20% and an OR as low as
1.10 at a 2-sided P value less than .05.32 The association at
APBB2 rs59892895 was validated, with the risk C allele
associated with increased risk of primary open-angle glau-
coma (OR, 1.13 [95% CI, 1.07-1.20]; P < .001; Figure 3). There
was no significant heterogeneity across all sites analyzed
(P value for heterogeneity = .15).
Table. Summary of Case-Control Collections in a Study of the Association of Genetic Variants
With Primary Open-Angle Glaucoma Among IndividualsWith African Ancestry
Sample Collectiona
rs59892895*C Present, % Sample Size, No.
Individuals
With Primary
Open-Angle
Glaucoma
Control
Individuals
Without Primary
Open-Angle
Glaucoma
Individuals
With Primary
Open-Angle
Glaucoma
Control
Individuals
Without Primary
Open-Angle
Glaucoma
GWAS Discovery
Ghana 26.9 23.3 833 896
Nigeria 30.4 22.6 554 348
South Africa 31.1 22.9 228 269
United States 26.1 21.7 705 608
Total 2320 2121
First Validation
Women’s Health Initiative 23.1 20.8 1720 6067
Kaiser Permanente GERA 23.3 18.4 300 2700
ADAGES 24.3 21.4 1890 2205
South Africa 13.0 14.4 297 147
Tanzania 30.1 28.3 366 329
United States 23.6 22.6 450 1350
South London 26.6 21.6 378 217
Total 5401 13 015
Second Validation
Cameroon 31.3 29.0 56 57
Nigeria 28.6 26.2 231 61
Nigeria (Kaduna) 29.2 30.2 99 88
Nigeria (African Glaucoma
Genetics Project)
32.6 31.0 131 71
Saudi Arabia 5.5 3.1 276 655
Brazil 8.8 4.5 399 460
The Democratic Republic
of the Congo
37.7 33.9 124 120
Morocco 6.8 3.5 37 130
Peru 2.0 1.2 51 128
Mali 27.3 23.4 132 132
Total 1536 1902
All validation 6937 14 917
Total samples 9257 17 038
Abbreviations: ADAGES, African
Descent and Glaucoma Evaluation
Study; GERA, Genetic Epidemiology
Research on Adult Health
and Aging; GWAS, genome-wide
association study.
a The study site (country) or name of
the study that the sample collection
was taken from. More information
on the sample collections can be
found in the eAppendix in the
Supplement.
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A second validation meta-analysis for this association
was completed with an additional 1536 affected individuals
and 1902 unaffected individuals with African ancestry
(Table). A significant association between the rs59892895*C
allele and increased risk of primary open-angle glaucoma
was observed (OR, 1.30 [95% CI, 1.12-1.51]; P < .001;
Figure 3), with no significant heterogeneity across all 10
sites analyzed (P value for heterogeneity = .27). An overall
meta-analysis of rs59892895*C involving the 9257 individu-
als with primary open-angle glaucoma and 17038 individu-
als without primary open-angle glaucoma from all cohorts
showed consistent association with primary open-angle
glaucoma risk (OR, 1.19 [95% CI, 1.14-1.25]; P < .001)
(Figure 3). The rs59892895*C allele was observed to not be
significantly associated with IOP and vertical cup-to-disc
ratio (P = .62) in an analysis of 6179 individuals of African
ancestry with available data.
Only individuals of African ancestry or individuals
with African ancestry admixture (eg, Brazil, Morocco, Peru,
and Saudi Arabia; Table) were polymorphic at APBB2
rs59892895—the rs59892895*C risk allele was not present
in European, South Asian, or East Asian individuals
(eFigure 4 in the Supplement). The sources of data accessed
to ascertain the frequency of rs59892895 in partici-
pants with other ancestries were from the 1000 Genomes
Project browser33 (eFigure 5 in the Supplement), the
Genome Aggregation Database (gNOMAD; eTable 3 in the
Supplement),34 as well as previously published GWAS data
sets of European3 (eAppendix in the Supplement) and Asian
individuals.15,35 No SNP within the broad APBB2 locus was
Figure 1. Discovery Analysis of 2320 IndividualsWith Primary Open-Angle Glaucoma and 2121 Age-Matched
Control Individuals
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genome-wide association discovery
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are included in this figure. The blue
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for suggestive statistical significance
commonly used in genome-wide
association studies (P = 10−5) and the
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Figure 2. Association at the Amyloid-βA4 Precursor Protein-Binding Family BMember 2 (APBB2) Locus on Chromosome 4
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The association between single-nucleotide polymorphisms (SNPs) and primary
open-angle glaucomawere plotted by genomic position on chromosome 4 and
degree of statistical significance. The horizontal line shows the threshold for
genome-wide significance, P = 5 × 10−8. The dots indicate the extent of linkage
disequilibrium (LD) between each tested SNPwith rs59892895 (based on
pairwise r2 values calculated from the discovery analysis). LD refers to the
association between alleles of SNPs located close to one another on the same
chromosome; SNPs in strong LD can serve as proxies for one another. Estimated
recombination rates were plotted in light blue to reflect the LD structure in
individuals with African ancestry. The estimated recombination rate shows the
average frequency in which recombination occurs at a particular location. The
extent of LD drops with increasing recombination rate. The horizontal lines
accompanied by arrows in the lower panel of the plot reflect the genes mapping
to the given genomic locations. The arrows indicate the direction of
transcription of the genes. The horizontal lines labeled APBB2 and RBM47
reflect 2 different gene transcripts of different lengths for both genes.
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significantly associated with primary open-angle glaucoma
in previously studied European or Asian ancestry case-
control collections (eFigure 6 in the Supplement). APBB2
rs59892895T>C was not observed to be in linkage disequi-
librium (defined as pairwise r2 > 0.8) with other coding
genetic variants or with potentially functional regulatory
elements (eFigure 7 in the Supplement).
Post Hoc Evaluation of Previously Described Loci and Their
Consequences on Risk in the Cohorts
Analysis of 26 well-validated primary open-angle glaucoma
SNPs from studies of individuals of European and Asian
ancestry showed that for 23 of the 26 SNPs, the ORs in par-
ticipants with African ancestry were smaller than in indi-
viduals with European ancestry. Heterogeneity tests
showed 19 of the SNPs had P values for heterogeneity of less
than .05 in support of a smaller OR in participants with
African ancestry compared with European individuals
(eTable 4 and eFigure 8 in the Supplement). Assessment of
the relationship between IOP loci13,30 and primary open-
angle glaucoma risk showed a weak correlation between IOP
and primary open-angle glaucoma risk in individuals with
African ancestry (eTable 5 and eFigure 9 in the Supple-
ment). Assessment of the relationship between vertical cup-
to-disc ratio loci36 and primary open-angle glaucoma risk
showed that all previously reported loci for vertical cup-to-
disc ratio were not associated with primary open-angle
glaucoma risk in participants with African ancestry
(eTable 6 in the Supplement).
Post Hoc Studies Exploring Potential Pathogenic
Mechanisms Related toAPBB2
All donor retina tissues were from individuals of African
ancestry. For primary visual cortex tissues, carriers of
the APBB2 rs59892895*C risk allele were of African
ancestry, whereas 3 of the 4 individuals with the APBB2
rs59892895*TT homozygous baseline genotype were of
European ancestry to match for the Braak stage of Alzhei-
mer disease diagnosis (eTable 2 in the Supplement). Explor-
atory analyses using immunohistochemistry on donor
retina and primary visual cortex tissues (eTable 1 and
eTable 2 in the Supplement) suggested that participants car-
rying the rs59892895*C risk allele had associated higher
APBB2 expression as well as associated increased staining
Figure 3. Association Between Amyloid-βA4 Precursor Protein-Binding Family BMember 2 (APBB2) rs59892895
and Primary Open-Angle Glaucoma Risk
Decreased
Risk
Increased
Risk P Value
0.5 71
Odds Ratio (95% CI)
No. of Samples
Genotyped
Affected
Individuals
Affected
Individuals
Unaffected
Individuals
Unaffected
Individuals
APBB2 rs59892895*C
Risk Alleles/No. Total Alleles
Collection
Odds Ratio
(95% CI)
694 596 362/1388 259/1192GWAS United States 1.27 (1.06-1.53)
821 884 411/1768442/1642GWAS Ghana 1.22 (1.04-1.42)
547 345 332/1094 156/690GWAS Nigeria 1.49 (1.20-1.86)
222 256 138/444 117/512GWAS South Africa 1.52 (1.14-2.03)
2.0 × 10–8GWAS discovery summary 1.32 (1.20-1.46)
<.001First validation meta-analysis 1.13 (1.07-1.20)
1720 6067 794/3440 2523/12 134Women’s Health Initiative 1.09 (1.00-1.19)
300 2700 140/600 991/5400Kaiser Permanente 1.35 (1.09-1.67)
1890 2205 918/3780 942/4410ADAGES 1.18 (1.06-1.31)
297 146 77/594 42/292South Africa 0.77 (0.49-1.22)
366 329 220/732 186/658Tanzania 1.11 (0.87-1.41)
450 1350 212/900 610/2700United States 1.05 (0.88-1.26)
378 215 201/756 93/430South London 1.40 (1.04-1.89)
56 57 35/112 33/114Cameroon 1.12 (0.63-1.97)
231 61 132/462 32/122Nigeria 1.12 (0.72-1.77)
96 86 56/192 52/172Nigeria (Kaduna) 0.95 (0.61-1.49)
129 71 84/258 44/142Nigeria (AGGP) 1.08 (0.70-1.68)
275 600 30/550 37/1200Saudi Arabia 1.81 (1.11-2.97)
399 447 70/798 40/894Brazil 2.05 (1.38-3.07)
122 118 92/244 80/236The Democratic Republic of the Congo 1.18 (0.81-1.71)
37 130 5/74 9/260Morocco 2.02 (0.66-6.22)
51 128 2/102 3/256Peru 1.69 (0.53-5.40)
132 128 72/264 60/256Mali 1.23 (0.82-1.82)
<.001Second validation meta-analysis 1.30 (1.12-1.51)
<.001All samples 1.19 (1.14-1.25)
The oblong data markers represent odds ratios, with the height of the data
markers being inversely proportional to the standard error of the odds ratio.
The diamonds represent the odds ratios after themeta-analysis, with the width
representing the 95% CIs. Collections from the United States were taken from
an African American population and the collection from South London was
taken from aWest African population. ADAGES indicates African Descent
and Glaucoma Evaluation Study; AGGP, African Glaucoma Genetics Project;
GWAS, genome-wide association study.
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for β-amyloid compared with participants homozygous for
the baseline rs59892895*T nonrisk allele (eFigures 10, 11,
and 12 in the Supplement).
Discussion
This studyof 26295 individuals founda genetic variant in the
APBB2 gene that was associatedwith a higher risk of primary
open-angle glaucoma. The genetic association between pri-
mary open-angle glaucoma and APBB2was observed only in
individuals of African ancestry. The level of genetic diversity
in participants of African ancestry was higher than in indi-
viduals of EuropeanorAsian ancestry, and the functional risk
alleles in APBB2 may not be present in these other popula-
tions. The increased risk associatedwith theAPBB2 allele ap-
pearednot tobemediatedvia increased IOPoropticnerveneu-
ropathyassociatedwithan increasingvertical cup-to-disc ratio,
thus suggesting a new insight to primary open-angle glau-
coma disease pathogenesis.
Because theodds ratioof theAPBB2 rs59892895*C risk al-
lele on primary open-angle glaucoma appeared to be larger in
populationswithAfricanancestry admixture, suchas inSaudi
Arabia, Brazil, Peru, and Morocco, this raised the possibility
that estimates from these4populations couldhavebeen con-
foundedbypopulation stratification.However, principal com-
ponent analysis of ancestry-informativemarkers fromBrazil,
Peru, andMorocco,whichhad sufficientDNA to allowassess-
ment of these additional markers, revealed little evidence of
population stratificationbetween affected andunaffected in-
dividuals (eFigure 13 in the Supplement).
Because APBB2was shown to be involved in the amyloi-
dogenic pathway of APP processing, an exploratory analysis
of human retinal and primary visual cortex tissues suggested
apotential relationshipbetween theAPBB2 rs59892895*C risk
allele, increasedAPBB2 expression, and associated increased
β-amyloid plaque deposition. Primary open-angle glaucoma
neurotoxicity may result from incomplete clearance of amy-
loid β and other neurotoxins from the interstitial space of the
optic nerve.37 However, there has been no conclusive evi-
dence that these pathways contribute to primary open-angle
glaucoma in humans.
The present analysis suggests that the majority of open-
angle glaucoma genetic loci described in individuals of Euro-
peanorAsian ancestry have amuchmoremodest effect in in-
dividuals of African ancestry. Also, in contrast to studies of
European individuals, the present data on individuals of
African ancestry showed amuchweaker correlation between
genetic factorscontributing to increasedIOPandprimaryopen-
angle glaucoma risk. It is possible that these differences in ge-
netic architecture are, at least in part, responsible for the in-
creased prevalence and severity of primary open-angle
glaucoma in African ancestry populations.
Limitations
This study has several limitations. First, despite the moder-
ately large sample size of participants of African ancestry,
there was only sufficient statistical power to detect associa-
tions with common genetic variants. Second, although all
study sites used well-established clinical protocols to diag-
nose primary open-angle glaucoma, the heterogeneity of
the primary open-angle glaucoma phenotype may have lim-
ited the ability to detect some genetic associations by bias-
ing the effect estimates toward the null. Third, while the
association observed between APBB2 rs59892895 and pri-
mary open-angle glaucoma risk was statistically significant,
the causal mechanisms of association have yet to be eluci-
dated. Fourth, because the observations from human retinal
and visual cortex tissues in this report are based on limited
sample sizes, they are interpreted here as exploratory and
hypothesis generating, and would require further validation
through future research.
Conclusions
In this GWAS, variants at the APBB2 locus demonstrated dif-
ferential associationwithprimaryopen-angleglaucomabyan-
cestry. If validated inadditional populations thismayhave im-
plications for risk assessment and therapeutic strategies.
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